By Cristina Gallardo
Novo Nordisk launched NovoCare Pharmacy, to deliver doses of its weight-loss Wegovy drug directly to its users, in a bid to reduce its cost.
The Danish pharmaceutical company said Wednesday that the new direct-to-patient delivery option will allow Wegovy users to receive all dose strengths of the drug at a reduced cost of $499 per month.
Uninsured patients and those with insurance that doesn't cover obesity drugs would also be able to make use of this offer, the group said.
NovoCare Pharmacy arrives at a time of increased competition in the booming market for weight-loss drugs, still led by Eli Lilly and Novo Nordisk, which nonetheless are seeing smaller rivals such as Roche, Pfizer and Amgen striving to challenge them.
The announcement comes a couple of weeks after the U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's blockbuster GLP-1 drugs, Wegovy and Ozempic, had been resolved.
All dose strengths of Wegovy are either meeting or surpassing current and projected U.S. demand, the pharmaceutical company said.
Shares in Novo Nordisk were up 2.3% at 630.10 Danish kroner in afternoon trading.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
March 05, 2025 09:57 ET (14:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。